Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc. is expected to maintain high single-digit organic growth in the future driven by the acquisition of new clients and contractual price adjustments, with a focus on achieving a long-term margin expansion target of 20%. The company reported better-than-expected fourth-quarter results, which reflects positive traction with its Ignite platform and an overall improving profitability outlook. Additionally, opportunities for value creation exist through asset monetization, such as VitalWare, which could provide a path forward amidst current challenges in its core data infrastructure platform.

Bears say

Health Catalyst Inc. is facing several challenges that could impact its financial performance negatively, as indicated by its recent third-quarter results and outlook for 2026. The company is reporting a decline in organic revenue and has lowered future revenue guidance, anticipating a 2-3% year-over-year decrease, reflecting headwinds from client migrations to a lower-cost platform and general economic uncertainty. Additionally, guidance for the first quarter of 2026 shows significant year-over-year revenue declines, coupled with disappointing adjusted EBITDA projections, highlighting concerns regarding customer attrition and the overall health of the purchasing environment for its services.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.